|
U.S. advisers say keep Glaxo diabetes drug on market |
|
Wednesday, 14 July 2010 00:00 |
|
(Reuters) - GlaxoSmithKline Plc's diabetes drug Avandia should be allowed to stay on the market but with additional warnings, U.S. health advisers recommended on Wednesday, easing a threat of further costly litigation that could have followed a ban.
|